Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG
The EMA has authorised Breyanzi (lisocabtagene maraleucel) for specified lymphomas, including large B-cell diffuse and follicular lymphoma, …
-
EMA approval · 2026-07-02EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH
The EMA authorises Lunsumio (mosunetuzumab) from Roche Registration GmbH for follicular lymphoma with conditional approval and orphan design…
-
EMA approval · 2026-06-08EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
The EMA authorises Yescarta (axicabtagene ciloleucel) for certain lymphomas, indicating market authorization and orphan designation.
-
EMA approval · 2026-03-12EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
EMA authorised Yescarta (axicabtagene ciloleucel) from Kite Pharma EU B.V. for treatment of certain B-cell lymphomas including follicular ly…
-
EMA approval · 2026-03-12EMA Authorised: Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto
EMA authorised Lenalidomide Krka (lenalidomide hydrochloride monohydrate) for several hematologic malignancies, including multiple myeloma, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-16EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH
The EMA authorised Lunsumio (mosunetuzumab) for follicular lymphoma with conditional approval and orphan medicine designation granted to Roc…
-
EMA approval · 2025-12-18EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Breyanzi (lisocabtagene maraleucel) for additional lymphomas, including diffuse large B-cell lymphoma and follicular lymp…
-
FDA approval · 2025-10-27FDA Approved: COLUMVI — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Columvi (glofitamab) submitted by Genentech, Inc.
-
FDA approval · 2025-10-17FDA Approved: GAZYVA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for GAZYVA (obinutuzumab) from Genentech to expand its approved indications.
-
EMA approval · 2025-09-19EMA Authorised: Ordspono (odronextamab) — Regeneron Ireland Designated Activity Company (DAC)
The European Medicines Agency has authorised Ordspono (odronextamab) from Regeneron Ireland DAC for follicular lymphoma with conditional app…
-
FDA approval · 2025-05-22FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)
FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
FDA approval · 2025-01-31FDA Approved: LENALIDOMIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic lenalidomide (LENALIDOMIDE) under an Original Application (ANDA 216213).
-
FDA approval · 2024-09-11FDA Approved: LENALIDOMIDE — Original Application (Novugen Pharma (USA) LLC)
FDA approved the original application for lenalidomide from Novugen Pharma (USA) LLC, enabling a generic version of the cancer drug lenalido…
-
FDA approval · 2024-02-26FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
FDA approval · 2024-01-11FDA Approved: BELRAPZO — Supplemental Application (Eagle Pharmaceuticals, Inc)
The FDA approved a supplemental application for Belrapzo (bendamustine hydrochloride) submitted by Eagle Pharmaceuticals, Inc. The action up…
-
FDA approval · 2023-10-05FDA Approved: LENALIDOMIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals USA Inc. under ANDA210154, updating the lena…
-
FDA approval · 2023-06-15FDA Approved: COLUMVI — Original Application (Genentech, Inc.)
FDA approved Columvi (glofitamab) from Genentech via an original biologics license application. The approval covers use in adults with relap…
-
FDA approval · 2023-06-05FDA Approved: BENDAMUSTINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved the original application for Bendamustine HCl from Meitheal Pharmaceuticals Inc., sanctioning a generic version of bendamus…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for lenalidomide (ANDA211022), authorizing the marketing of a generic lenalidomide prod…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.